The present invention relates to novel compounds that are inhibitors of TAM (Axl, Mer, and Tyro3) and / or Met family receptor tyrosine kinases (RTK). These compounds are suitable for the treatment of disorders related to, associated with, caused by, or induced by the TAM family of receptors (particularly hyperactivity of the TAM family of receptors). The compounds are suitable for the treatment of hyperproliferative disorders such as cancer, especially immunosuppressive cancer, refractory cancer, and cancer metastasis.